The Karl Landsteiner Institute for Lung Research and Pulmonary Oncology is dedicted to clinical trials to evaluate the safety and efficacy of oncologic therapies in patients with lunger cancer as well as establishing pharmacological and non-pharmacological treatment options in patients with COPD and interstitial lung disease. While we are conducting "real-life" studies, we are also participating in national and international registry studies with the aim of achieving a better understanding of the course of pneumological diseases and their success in treatment. Furthermore, we established the Landsteiner Lung Cancer Research Platform (LALUCA), which is a prospective lung cancer registry with a primary focus on diagnostic processes, therapeutic decisions, and prognosis in clinical practice.